Accesswire
15 Jun 2026, 10:40 UTC · 22w ago
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
Impact · against what's priced in
Precigen gains significant valuation support through a combination of regulatory protection and clinical validation. The FDA's orphan drug exclusivity through 2032 removes immediate competitive threats, while the 83% three-year durability rate strengthens the drug's position as the potential standard of care for RRP.
- PGEN+0.70
No priced-in read yet





